PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences:
Detailed price information for Boston Scientific Corp (BSX-N) from The Globe and Mail including charting and trades.
PTC Therapeutics (PTCT) is back in focus after its third quarter, when revenue of US$357.81 million topped analyst forecasts and management lifted full year sales guidance for 2026. Despite the upbeat third quarter and higher 2026 revenue guidance, PTC Therapeutics’ share price has slipped, with a 1-month share price return of down 7.43% and a year to date share price return of down 21.85%. At the same time, the 3-year total shareholder return is up about 3x and the 5-year total shareholder...
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Oct. 28, 2026, the company approved non-statutory stock options to purchase an aggregate of 9.620 shares of its common stock and 11,535 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to 13 new employees. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hires' employment compensation.
PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its third quarter 2026 financial results and provide a business update on Thursday, Oct. 29, 2026, at 4:30 p.m. ET.
Detailed price information for Ptc Therapeutics (PTCT-Q) from The Globe and Mail including charting and trades.
PTC Therapeutics (PTCT) said late Monday it completed the acquisition of ST-920, a gene therapy for
PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that it completed the previously announced agreement with Sangamo Therapeutics, Inc. to acquire ST-920 – a BLA-stage, one-time administered AAV gene therapy for Fabry disease. A rolling BLA submission to FDA for accelerated approval of ST-920 is expected to be completed in Q4 2026.
PTC Therapeutics (PTCT) heads into its next earnings report with consensus EPS forecasts unchanged over the past month, even as the stock ticked 0.6% higher in the last session to close at $68. Recent trading has been choppy for PTC Therapeutics, with the share price down 3.9% over the last session to $65.37 and weaker momentum over the past quarter. However, the 3-year total shareholder return of 173.3% and 5-year total shareholder return of 66.4% still reflect a materially stronger long-run...
Detailed price information for Ptc Therapeutics (PTCT-Q) from The Globe and Mail including charting and trades.
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences:
This is the newest page. Registered accounts read further back.